{"id":"W4220714022","doi":"10.1158/1538-7445.sabcs21-p5-17-05","title":"Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with <i>PIK3CA</i>-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Breast cancer; Oncology; Cancer; Combination therapy; Phases of clinical research; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00134578,0.001791157,0.001813863,0.0006445684,0.00040083,0.001472356,0.001326,0.001206181,0.005149898],"category_scores_gemma":[0.0007539992,0.0006662456,0.00146396,0.0005798643,0.001178222,0.0008149387,0.0004136497,0.004438681,0.001628551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001241232,"about_ca_system_score_gemma":0.002622788,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002120588,"about_ca_topic_score_gemma":0.004156283,"domain_scores_codex":[0.9995863,0.0001771813,0.00001950122,0.0000699532,0.00004180093,0.0001052146],"domain_scores_gemma":[0.9993783,0.00006463106,0.00008242758,0.00004540312,0.0000456709,0.0003835148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6396204,0.1187443,0.006513533,0.001345497,0.002299999,0.0006006479,0.0004477529,0.004874874,0.07447319,0.0008539392,0.009946344,0.1402796],"study_design_scores_gemma":[0.4874799,0.4901242,0.007310605,0.00007341065,0.0007032487,0.0004208651,0.0001056273,0.001432012,0.006610529,0.0003367255,0.005364217,0.0000386903],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800237,0.002654092,0.001301489,0.0007909125,0.0001820304,0.00574269,0.00373512,0.000285061,0.005284897],"genre_scores_gemma":[0.972932,0.003115198,0.002921199,0.00160213,0.0002246385,0.004056358,0.007691198,0.0001060617,0.007351219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005149898,"threshold_uncertainty_score":0.01722813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03702796251358815,"score_gpt":0.3804772975894919,"score_spread":0.3434493350759038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}